Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial - Autio, Karen A; Dreicer, Robert; Anderson, Justine; Garcia, Jorge A; Alva, Ajjai; Hart, Lowell L; Milowsky, Matthew I; Posadas, Edwin M; Ryan, Charles J; Graf, Ryon P; Dittamore, Ryan; Schreiber, Nicole A; et al. (JAMA oncology, 2018)
Keywords: Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Diarrhea - chemically induced; Disease-Free Survival; Docetaxel - adverse effects; Docetaxel - therapeutic use; Fatigue - chemically induced; Humans; Male; Middle Aged; Nanoparticles - adverse effects; Nanoparticles - therapeutic use; Nausea - chemically induced; Neoplasm Metastasis; Prostate-Specific Antigen - antagonists & inhibitors; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - metabolism; Prostatic Neoplasms, Castration-Resistant - pathology; Treatment Outcome